Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

316
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
316
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

225
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
225
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

1.9K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.9K
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

4.2K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.2K
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

3.7K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.7K
Bioequivalence: Overview01:16

Bioequivalence: Overview

1.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

STN-DBS and LCIG differentially affect long-term axial symptoms in Parkinson's disease.

NPJ Parkinson's disease·2026
Same author

Kinematic Features of Voluntary and Involuntary Head Movements in Cervical Dystonia.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Nutritional Care of Patients with Parkinson's Disease.

Nutrition reviews·2026
Same author

Mapping the Silent Onset of Parkinson's Disease: Monoamine Imaging in the Era of the Race for Preclinical Intervention.

Current neurology and neuroscience reports·2026
Same author

Expanding the phenotypic spectrum of SOD1‑related ALS: upper motor neuron predominance in a p.D91A case.

Neurodegenerative disease management·2026
Same author

Age-Specific Parkinson Disease Risk in Gaucher Disease Type 1: Data From the ICGG Gaucher Registry.

Neurology·2026

Related Experiment Video

Updated: Aug 2, 2025

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

3.8K

Levodopa Equivalent Dose of Safinamide: A Multicenter, Longitudinal, Case-Control Study.

Roberto Cilia1, Emanuele Cereda2, Marco Piatti3,4

  • 1Department of Clinical Neurosciences, Parkinson and Movement Disorders Unit Fondazione IRCCS Istituto Neurologico Carlo Besta Milan Italy.

Movement Disorders Clinical Practice
|April 18, 2023
PubMed
Summary

This study established Levodopa equivalent dose (LED) conversion factors for safinamide and rasagiline in Parkinson's disease (PD) patients. Safinamide 100mg was equivalent to 125mg LED, while 50mg safinamide and rasagiline 1mg were both 100mg LED.

Keywords:
LEDParkinson's diseaseRasagilinelevodopa equivalent dosesafinamide

More Related Videos

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.8K
The 6-hydroxydopamine Rat Model of Parkinson's Disease
08:10

The 6-hydroxydopamine Rat Model of Parkinson's Disease

Published on: October 27, 2021

11.0K

Related Experiment Videos

Last Updated: Aug 2, 2025

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

3.8K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.8K
The 6-hydroxydopamine Rat Model of Parkinson's Disease
08:10

The 6-hydroxydopamine Rat Model of Parkinson's Disease

Published on: October 27, 2021

11.0K

Area of Science:

  • Neurology
  • Pharmacology
  • Clinical Research

Background:

  • Levodopa equivalent dose (LED) is crucial for comparing dopaminergic medications in Parkinson's disease (PD).
  • Current LED estimations for MAO-B inhibitors (iMAO-B) like safinamide and rasagiline rely on empirical methods.
  • Standardized LED conversion factors are needed for these iMAO-B treatments.

Purpose of the Study:

  • To estimate the Levodopa equivalent dose (LED) for safinamide at 50mg and 100mg doses.
  • To provide a more rigorous basis for comparing safinamide with other iMAO-B treatments.

Main Methods:

  • A multicenter, longitudinal, case-control study involving 500 PD patients with motor complications.
  • Retrospective review of clinical charts for patients treated with safinamide (50mg or 100mg), rasagiline (1mg), or no iMAO-B.
  • Analysis of clinical outcomes and medication dosages over an 8-10 month follow-up period.

Main Results:

  • After adjusting for baseline and clinical factors, safinamide 100mg was found to be equivalent to 125mg LED.
  • Safinamide 50mg and rasagiline 1mg were found to be equivalent to 100mg LED.
  • Patients on safinamide showed improvements in motor function scores (UPDRS-III) and reduced OFF-time (UPDRS-IV) compared to controls.

Conclusions:

  • A rigorous method was employed to calculate LED for safinamide 50mg and 100mg.
  • The findings provide valuable LED conversion factors for safinamide in PD management.
  • Prospective pragmatic trials are recommended to validate these LED estimations.